Skip to main content
Premium Trial:

Request an Annual Quote

Schering to Float Genomics Business in 2001 - Reuters

NEW YORK, Sept 6 German pharmaceuticals group Schering AG intends to float its functional genomics biotech business next year, Reuters reported on Wednesday.

Schering said that the offering would take place after the company raises as much as $35 million in venture capital for the unit. “Venture capitalists will provide 30-40 million euros, then there will be a further capital rise in which we don't take part and don't sell any of our shares,” Chief Financial Officer Klaus Pohle told reporters in Berlin. “We want to be careful...we have seen recently that many new companies have come onto the bourse without the ideal quality. We want the company to have a high quality when the IPO comes and that costs time,'” Pohle said.

Functional genomics comprises part of Schering's biotech activities, which have resulted in such hits as multiple sclerosis drug Betaferon and non-Hodgkins lymphoma drugs Zevalin and Oncolym.

Pohle did not comment on potential investors.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.